Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Rhea-AI Summary
Akero Therapeutics (NASDAQ:AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.
The presentation is scheduled for September 8, 2025, at 10:45 a.m. E.T. in New York. Investors can access the live webcast through Akero's investor relations website, with an archived replay available after the event.
Positive
- None.
Negative
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors watch Akero Therapeutics' Morgan Stanley conference presentation?
What type of company is Akero Therapeutics (AKRO)?
Where will the Morgan Stanley Healthcare Conference 2025 with Akero Therapeutics be held?
